Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,797
archived clinical trials in
Peripheral Vascular Disease

A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Royal Oak, MI
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Royal Oak, MI
Click here to add this to my saved trials
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Minneapolis, MN
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Kansas City, MO
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
New York, NY
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Statesville, NC
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Statesville, NC
Click here to add this to my saved trials
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Cincinnati, OH
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Cleveland, OH
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Houston, TX
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Seattle, WA
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated:  8/1/2016
mi
from
Montreal,
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors
Status: Enrolling
Updated: 8/1/2016
mi
from
Montreal,
Click here to add this to my saved trials
A Multiple Ascending Dose Study of RO4905417 in Healthy Volunteers and Patients With Peripheral Arterial Disease (PAD).
A Randomized, Double-Blind, Multiple-Ascending Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO4905417 Following Intravenous Infusion in Healthy Volunteers and Patients With Peripheral Arterial Disease
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Gainesville, FL
A Multiple Ascending Dose Study of RO4905417 in Healthy Volunteers and Patients With Peripheral Arterial Disease (PAD).
A Randomized, Double-Blind, Multiple-Ascending Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO4905417 Following Intravenous Infusion in Healthy Volunteers and Patients With Peripheral Arterial Disease
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Gainesville, FL
Click here to add this to my saved trials
A Multiple Ascending Dose Study of RO4905417 in Healthy Volunteers and Patients With Peripheral Arterial Disease (PAD).
A Randomized, Double-Blind, Multiple-Ascending Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO4905417 Following Intravenous Infusion in Healthy Volunteers and Patients With Peripheral Arterial Disease
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Cincinnati, OH
A Multiple Ascending Dose Study of RO4905417 in Healthy Volunteers and Patients With Peripheral Arterial Disease (PAD).
A Randomized, Double-Blind, Multiple-Ascending Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO4905417 Following Intravenous Infusion in Healthy Volunteers and Patients With Peripheral Arterial Disease
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Multiple Ascending Dose Study of RO4905417 in Healthy Volunteers and Patients With Peripheral Arterial Disease (PAD).
A Randomized, Double-Blind, Multiple-Ascending Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO4905417 Following Intravenous Infusion in Healthy Volunteers and Patients With Peripheral Arterial Disease
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
San Antonio, TX
A Multiple Ascending Dose Study of RO4905417 in Healthy Volunteers and Patients With Peripheral Arterial Disease (PAD).
A Randomized, Double-Blind, Multiple-Ascending Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO4905417 Following Intravenous Infusion in Healthy Volunteers and Patients With Peripheral Arterial Disease
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Multiple Ascending Dose Study of RO4905417 in Healthy Volunteers and Patients With Peripheral Arterial Disease (PAD).
A Randomized, Double-Blind, Multiple-Ascending Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO4905417 Following Intravenous Infusion in Healthy Volunteers and Patients With Peripheral Arterial Disease
Status: Enrolling
Updated:  8/1/2016
mi
from
Heidelberg,
A Multiple Ascending Dose Study of RO4905417 in Healthy Volunteers and Patients With Peripheral Arterial Disease (PAD).
A Randomized, Double-Blind, Multiple-Ascending Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO4905417 Following Intravenous Infusion in Healthy Volunteers and Patients With Peripheral Arterial Disease
Status: Enrolling
Updated: 8/1/2016
mi
from
Heidelberg,
Click here to add this to my saved trials
Patient-Reported Preferences Affecting Revascularization Decisions
Patient-Reported Preferences Affecting Revascularization Decisions
Status: Enrolling
Updated:  8/2/2016
Duke University Hospital
mi
from
Durham, NC
Patient-Reported Preferences Affecting Revascularization Decisions
Patient-Reported Preferences Affecting Revascularization Decisions
Status: Enrolling
Updated: 8/2/2016
Duke University Hospital
mi
from
Durham, NC
Click here to add this to my saved trials
School-Based Intervention to Increase Physical Activity Among Adolescent Females
Interventions to Increase Adolescent Physical Activity
Status: Enrolling
Updated:  8/2/2016
The University of Maryland
mi
from
College Park, MD
School-Based Intervention to Increase Physical Activity Among Adolescent Females
Interventions to Increase Adolescent Physical Activity
Status: Enrolling
Updated: 8/2/2016
The University of Maryland
mi
from
College Park, MD
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Birmingham, AL
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Northport, AL
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Northport, AL
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Phoenix, AZ
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Tucson, AZ
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Tucson, AZ
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Spring Valley, CA
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Spring Valley, CA
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Torrance, CA
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Torrance, CA
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Walnut Creek, CA
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Fort Lauderdale, FL
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Jacksonville, FL
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Pembroke Pines, FL
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Chicago, IL
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Indianapolis, IN
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Lacombe, LA
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Lacombe, LA
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Slidell, LA
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Slidell, LA
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Auburn, ME
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Auburn, ME
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
New York, NY
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Statesville, NC
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Statesville, NC
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Cincinnati, OH
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Oklahoma City, OK
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Camp Hill, PA
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Camp Hill, PA
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Philadelphia, PA
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Bryan, TX
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Bryan, TX
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Houston, TX
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
San Antonio, TX
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Salt Lake City, UT
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Norfolk, VA
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Norfolk, VA
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Richmond, VA
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated:  8/3/2016
GSK Investigational Site
mi
from
Buenos Aires,
SB-480848 In Subjects With Coronary Heart Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks
Status: Enrolling
Updated: 8/3/2016
GSK Investigational Site
mi
from
Buenos Aires,
Click here to add this to my saved trials
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Status: Enrolling
Updated:  8/10/2016
Hudson Heart Group, PC
mi
from
Guttenberg, NJ
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Status: Enrolling
Updated: 8/10/2016
Hudson Heart Group, PC
mi
from
Guttenberg, NJ
Click here to add this to my saved trials
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Status: Enrolling
Updated:  8/10/2016
Elmhurst Hospital
mi
from
Elmhurst, NY
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Status: Enrolling
Updated: 8/10/2016
Elmhurst Hospital
mi
from
Elmhurst, NY
Click here to add this to my saved trials
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Status: Enrolling
Updated:  8/10/2016
Winthorp University Hospital
mi
from
Mineola, NY
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Status: Enrolling
Updated: 8/10/2016
Winthorp University Hospital
mi
from
Mineola, NY
Click here to add this to my saved trials
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Status: Enrolling
Updated:  8/10/2016
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Status: Enrolling
Updated: 8/10/2016
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Status: Enrolling
Updated:  8/10/2016
Stony Brook University Hospital
mi
from
Stony Brook, NY
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Status: Enrolling
Updated: 8/10/2016
Stony Brook University Hospital
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Coronary Flow Reserve Following Orbital Atherectomy
Coronary Flow Reserve Following Orbital Atherectomy and Percutaneous Revascularization in Severely Calcified Coronary Lesions
Status: Enrolling
Updated:  8/10/2016
Chandler Regional Medical Center and Mercy Gilbert Medical Center
mi
from
Chandler, AZ
Coronary Flow Reserve Following Orbital Atherectomy
Coronary Flow Reserve Following Orbital Atherectomy and Percutaneous Revascularization in Severely Calcified Coronary Lesions
Status: Enrolling
Updated: 8/10/2016
Chandler Regional Medical Center and Mercy Gilbert Medical Center
mi
from
Chandler, AZ
Click here to add this to my saved trials